Please check your internet connection and try again.
# Miconazole vaginal pessary
## Overview
Miconazole is an imidazole antifungal agent that works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. It is available in vaginal pessary formulations for the treatment of vulvovaginal candidiasis.
## Primary Indications
* Treatment of vulvovaginal candidiasis (yeast infection) caused by susceptible Candida species.
## Adult Dosing
* **100 mg vaginal pessary:** Insert one pessary vaginally once daily at bedtime for 7 days.
* **200 mg vaginal pessary:** Insert one pessary vaginally once daily at bedtime for 3 days.
* **Disulfiram-like reaction:** Concomitant use with oral miconazole or certain other azoles may potentiate the effects of disulfiram.
## Pediatric Dosing
* **Safety and efficacy in pediatric patients have not been established for vaginal pessary formulations.**
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically necessary.
* **Hepatic Impairment:** No dose adjustment is typically necessary, but caution is advised due to potential systemic absorption, especially with prolonged use or in patients with hepatic disease.
## Contraindications
* Hypersensitivity to miconazole or any component of the formulation.
* Concurrent use with CYP3A4 substrates that have a narrow therapeutic index (e.g., terfenadine, astemizole, cisapride, simvastatin, lovastatin, midazolam, triazolam).
## Adverse Effects
* **Common:** Vaginal burning, itching, irritation, vulvar swelling, abdominal pain.
* **Less Common:** Headache, rash, urticaria.
## Key Drug Interactions
* **CYP3A4 Inhibitor:** Miconazole is a potent inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates can increase plasma concentrations of these drugs, potentially leading to serious adverse effects. Examples include:
* Warfarin (increased risk of bleeding)
* Sulfonylureas (increased risk of hypoglycemia)
* Phenytoin (increased phenytoin levels)
* Certain HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
* **CYP2C9 Inhibitor:** May increase INR in patients on warfarin.
## Monitoring
* Assess for symptom relief and resolution of infection.
* Monitor for adverse effects, particularly local irritation and signs of systemic absorption if used in large quantities or for prolonged periods.
* If using concomitantly with warfarin, monitor INR closely.
## Clinical Pearls
* Treatment should be completed even if symptoms improve before the course is finished.
* Avoid intercourse during treatment.
* If symptoms do not improve after 3 days of treatment or if infection recurs, consult a healthcare provider.
* Pessaries may weaken latex condoms and diaphragms; consider alternative contraceptive methods during treatment and for at least 72 hours after completion.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature before making clinical decisions. Dosing and recommendations may vary based on individual patient factors and local guidelines.
